Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB042C in Advanced Solid Tumors
NCT07192107Phase 2Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Nov 2025
- Primary completion
- Oct 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of MHB042C in solid tumor (advanced stage), sponsored by Minghui Pharmaceutical, Inc.. Started Nov 2025; status: recruiting.
02
Drugs
MHB042C
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07192107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192107.